Download PDF BrochureInquire Before Buying
The South Korea Long Read Sequencing Market is focused on using advanced DNA sequencing techniques that can read very long strands of genetic code, which is a major upgrade over older, shorter methods. This technology is becoming a powerful tool in South Korea’s bioscience and clinical sectors, particularly for getting a much clearer picture of complex genomes, figuring out structural genetic variations, and identifying disease origins, thereby driving advancements in highly accurate diagnostics and personalized medicine within the country.
The Long Read Sequencing Market in South Korea is expected to grow steadily at a CAGR of XX% between 2025 and 2030, rising from an estimated US$ XX billion in 2024-2025 to US$ XX billion by 2030.
The global long-read sequencing market was valued at $596 million in 2023, is estimated at $758 million in 2024, and is projected to reach $3,129 million by 2029, growing at a CAGR of 32.8%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140422082
Drivers
The Long Read Sequencing (LRS) market in South Korea is experiencing strong momentum, primarily driven by the nation’s intensive government investment and strategic focus on advancing genomic research and precision medicine. South Korea has established ambitious national initiatives aimed at sequencing thousands of native genomes, which necessitates the use of LRS technology for generating high-quality, comprehensive reference genomes capable of resolving complex structural variants (SVs) and repetitive regions that traditional Short Read Sequencing (SRS) often misses. This governmental support fosters a fertile research environment, attracting both local and international technology providers. A key clinical driver is the growing application of LRS in oncology and rare disease diagnostics. LRS enables superior detection of fusion genes, complex rearrangements, and epigenetic modifications, which are critical for accurate cancer characterization and personalized treatment planning. Furthermore, the strong integration of advanced high-throughput sequencing technologies within South Korea’s leading academic and clinical institutions accelerates the adoption and commercialization of LRS platforms. Finally, the local presence of a robust bioinformatics and IT sector facilitates the handling and analysis of the large, complex datasets generated by LRS, supporting its utility in large-scale population health studies and clinical pipelines.
Restraints
Despite its significant scientific advantages, the South Korean LRS market is constrained by several factors, most notably the high initial cost and maintenance expenditure associated with LRS platforms and reagents. Compared to established Short Read Sequencing technologies, LRS instruments and consumables carry a premium price tag, which can limit widespread accessibility, particularly for smaller laboratories and clinics operating under tighter budgets. Another major restraint is the complex and computationally intensive nature of LRS data analysis. The longer reads generate data files that require specialized, powerful computational infrastructure and advanced bioinformatic expertise to process, align, and interpret accurately. There is a recognized shortage of highly trained bioinformaticians and technicians in South Korea specifically skilled in LRS data pipelines, posing a bottleneck for throughput and efficiency. Furthermore, while the technology is powerful, the overall throughput, though improving, is generally lower than mature SRS platforms, which can deter high-volume clinical applications. Finally, regulatory pathways for LRS-based diagnostic tests, particularly those detecting novel structural variants, are still maturing, which can slow the transition of promising research applications into reimbursed clinical services under the National Health Insurance Service (NHIS).
Opportunities
Substantial opportunities exist for the expansion of the Long Read Sequencing (LRS) market in South Korea by capitalizing on emerging clinical and research demands. A major opportunity lies in establishing LRS as the standard for non-invasive prenatal testing (NIPT) and comprehensive genomic profiling in oncology. LRS offers improved resolution for detecting chromosomal abnormalities and complex mutations, which could position it as a superior diagnostic tool once costs become more competitive. Furthermore, the strong emphasis on developing biopharmaceuticals and advanced cell and gene therapies in South Korea provides a vital market for LRS in quality control and process development. LRS is essential for verifying the integrity of engineered cell lines and vector sequences, ensuring product safety and efficacy. The market can also benefit significantly from commercializing streamlined, user-friendly LRS workflows combined with cloud-based analysis solutions tailored for the Korean clinical environment, reducing the reliance on highly specialized in-house bioinformatics teams. Collaborations between global LRS technology developers and major South Korean conglomerates (Chaebols) and domestic biotech firms present opportunities for localized manufacturing and wider clinical distribution, potentially lowering costs and accelerating domestic adoption.
Challenges
Key challenges facing the Long Read Sequencing (LRS) market in South Korea revolve around technical maturation and clinical adoption hurdles. A primary technical challenge remains the relatively high error rate in raw LRS data, which necessitates rigorous and complex error correction algorithms and deep sequencing coverage to ensure accuracy, increasing both cost and computational load. Another significant hurdle is the need for standardization of LRS library preparation and analysis protocols across different institutions to ensure result reproducibility, which is critical for clinical validation and cross-study comparison. Market penetration is also challenged by the deeply entrenched and validated infrastructure already supporting Short Read Sequencing (SRS), requiring LRS technologies to demonstrate clear and compelling clinical utility and cost-effectiveness to justify the transition. Educating clinicians and pathologists on the unique benefits and appropriate application of LRS is crucial but demanding, as many clinical labs are still accustomed to established SRS workflows. Finally, the successful integration of LRS data into existing hospital Electronic Health Record (EHR) systems poses interoperability and data security challenges that need robust, government-approved solutions.
Role of AI
Artificial Intelligence (AI) is integral to overcoming technical challenges and maximizing the clinical potential of Long Read Sequencing (LRS) in South Korea. AI algorithms, particularly machine learning models, are essential for improving the accuracy of base calling and significantly reducing the intrinsic error rates associated with LRS platforms, thereby increasing the reliability of results. In the data analysis pipeline, AI is crucial for automating the complex process of *de novo* genome assembly and the precise identification of structural variants, which are often overlooked by manual or traditional methods. Machine learning can be trained on massive genomic datasets to rapidly identify clinically relevant mutations and biomarkers from LRS data, accelerating diagnostic turnaround times in oncology and rare disease testing. Furthermore, AI contributes to optimizing LRS experiment design, sample preparation, and run conditions, leading to greater efficiency and cost reduction per sample. By automating interpretation and integrating genomic findings with patient phenotypic data, AI facilitates personalized treatment recommendations based on the comprehensive genomic insights provided by LRS technology, embedding it firmly within South Korea’s precision medicine framework.
Latest Trends
Several cutting-edge trends are defining the trajectory of the Long Read Sequencing (LRS) market in South Korea. A key trend is the accelerating deployment of portable LRS devices, which enable rapid, real-time sequencing outside of centralized research facilities, particularly valuable for infectious disease surveillance and outbreak response, building on recent public health experiences. There is also a pronounced trend toward multi-omic integration, where LRS is combined with other advanced techniques like single-cell sequencing and spatial transcriptomics to provide a more holistic view of biological systems, driving innovation in drug discovery and disease modeling. In terms of technology, the development of ultra-long read sequencing capabilities is a major focus, enabling complete sequencing of entire chromosomes and complex regions, which promises to revolutionize the study of human genetic variation and disease etiology. Furthermore, South Korean research is leaning heavily into applying LRS for comprehensive full-length RNA sequencing (isoform sequencing), providing unparalleled accuracy in gene expression analysis without the need for computational reconstruction. Lastly, the collaboration between LRS providers and local biobanks is trending, creating large, high-quality reference datasets that enhance the clinical utility of LRS specifically for the Korean population.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140422082